Form 4 Filing for BELITE BIO, INC.

On April 23, 2026, Nathan L. Mata, Chief Scientific Officer of BELITE BIO, INC., reported the sale of a total of 950.0 American depositary shares. These sales were executed under a Rule 10b5-1 trading plan adopted on December 10, 2025. The shares were sold in multiple transactions at prices ranging from $164.03 to $169.69 per share. The total post-transaction shares owned by Mr. Mata are 9666. The sales are categorized as direct ownership disposals.